Similar articles

• Survival after ABO-incompatible allogeneic bone marrow transplant after a preparative regimen of busulfan and cyclophosphamide.

  Kalaycioglu M, Copelan E, Avalos B, Klein J, Goormastic M, Bolwell B. Kalaycioglu M, et al. Bone Marrow Transplant. 1995 Jan;15(1):105-10. Bone Marrow Transplant. 1995. PMID: 7742742
• ABO incompatibility and relapse risk in patients undergoing allogeneic marrow transplantation for acute myeloid leukemia.

  Mielcarek M, Torok-Storb B, Storb R. Mielcarek M, et al. Bone Marrow Transplant. 2002 Oct;30(8):547-8; author reply 548. doi: 10.1038/sj.bmt.1703706. Bone Marrow Transplant. 2002. PMID: 12379898 No abstract available.
• Bone marrow transplantation for leukemia and aplastic anemia: management of ABO incompatibility.

  Curtis JE, Messner HA. Curtis JE, et al. Can Med Assoc J. 1982 Mar 15;126(6):649-55. Can Med Assoc J. 1982. PMID: 7039802 Free PMC article.
• Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin.

  Santamaría A, Sureda A, Martino R, Domingo-Albós A, Muñiz-Díaz E, Brunet S. Santamaría A, et al. Bone Marrow Transplant. 1997 Dec;20(12):1105-7. doi: 10.1038/sj.bmt.1701012. Bone Marrow Transplant. 1997. PMID: 9466287 Review.
• A new concept of accommodation in ABO-incompatible kidney transplantation.

  Takahashi K. Takahashi K. Clin Transplant. 2005;19 Suppl 14:76-85. doi: 10.1111/j.1399-0012.2005.00392.x. Clin Transplant. 2005. PMID: 15955174 Review.